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Abstract 
Ecstasy/MDMA use is proposed to cause damage to 5-HT axons in humans. Therefore, users 
should show deficits in cognitive processes that rely on, serotonin rich, prefrontal areas of the 
brain. However, there is inconsistency in findings to support this hypothesis. The aim of the 
current study was to examine deficits in executive functioning in ecstasy users compared to 
controls using meta-analysis. We identified k=39 studies, contributing 89 effect sizes, 
investigating executive functioning in ecstasy users and polydrug using controls. We 
compared function specific task performance in 1221 current ecstasy users and 1242 drug 
using controls, from tasks tapping the executive functions; updating, switching, inhibition and 
access to long term memory. The significant main effect demonstrated overall executive 
dysfunction in ecstasy users (SMD = -0.18, 95% CIs [-0.26, -0.11]; Z=5.05, p < .001, I2 = 
82%), with a significant subgroup effect (X2 = 22.06, df = 3, p < .001, I2 = 86.4%) 
demonstrating differential effects across executive functions. Ecstasy users showed 
significant performance deficits in access (SMD = -0.33, 95% CIs [-0.46, -0.19]; Z = 4.72, p 
< .001; I2 = 74%), switching (SMD = -0.19, 95% CIs [-0.36, -0.02]; Z = 2.16, p < .05; I2 = 
85%) and updating (SMD = -0.26, 95% CIs [-0.37, -0.15]; Z = 4.49, p < .001; I2 = 82%). No 
differences were observed in inhibitory control. We conclude that this is the most 
comprehensive analysis of executive function in ecstasy users to date and provides a 
behavioural correlate of potential serotonergic neurotoxicity. 
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Introduction 
Ecstasy (3,4-methylenedioxymethamphetamine: MDMA) remains popular despite 
reports of potential long-term negative consequences associated with repeated use (see 
Parrott, 2013). Furthermore, ecstasy poses a major public health concern due to an increase in 
recent MDMA related deaths (Anderson, 2014) as well as reported increases in tablet 
strength, with some sources suggesting tablets may contain upwards of 200mg of MDMA 
(Global Drugs Survey, 2015). Animal literature suggests that ecstasy causes damage to 
serotonin axons (Ricaurte, 1988: Molliver, 1990). There is also evidence of ecstasy-related 
alterations in mood (Curran et al., 2004) and long term changes in neuroendocrine function 
(Wetherell & Montgomery, 2014). However, perhaps public health warnings are not being 
taken seriously due to mixed messages in the media and scientific literature about relative 
harms of drugs (see, Nutt et al., 2010 for assessment of drug related harms, which poorly 
correlates with UK drug classification). 
 A recent review by Murphy et al. (2009) suggests that ecstasy related cognitive 
dysfunction is not consistently reported in the literature, thus monitoring of research is 
necessary to gain a coherent understanding of drug effects.  Executive functions (EFs) have 
been defined as a set of general-purpose control processes, required for regulating thought 
and action (Miyake & Friedman, 2012). Moreover, the central executive (CE) is an integral 
component of working memory (Baddeley, 2000) and is required for coordinating and 
processing information. Some of the apparent inconsistency in the literature may be 
attributable to several of the classic working memory/“executive” tasks requiring use of 
multiple EFs: a problem of task impurity (Miyake & Friedman, 2012). An influential EF 
framework suggested that the CE is not a unified construct; rather it is comprised of several 
correlated but distinctly separable functions (Miyake et al, 2000). Three discrete EFs were 
originally identified; mental set shifting/switching (“switching”), information updating and 
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monitoring (“updating”) and inhibition of prepotent responses (“inhibition”). A fourth 
component, “access” to semantic memory, was later added by Fisk and Sharp (2004). These 
are the 4 classic EFs that have been assessed in the literature. However it is interesting to note 
that more recent developments in the unity/diversity framework (Miyake & Freidman, 2012) 
suggest that inhibitory control no longer exists as an EF, as it is subsumed under the concept 
of working memory and EF in general.  
 Montgomery et al. (2005a) suggested that there may be a differential pattern of 
executive impairment based on previous drug use and type of function, whereby ecstasy-
related deficits were apparent in updating and access, but not in switching or inhibition. 
These conclusions were arrived at by administering tasks that are understood to assess one 
function only. As such, it may be that ecstasy users are impaired on some EFs and not others, 
supporting the unity and diversity framework (Miyake, et al 2000; 2012). There are nuances 
in the neuroanatomy underpinning each function, which may explain why impairment is 
potentially function specific. For example, the dorsolateral prefrontal cortex (DLPFC), is 
understood to be important for memory updating (Goldman-Rakic, 1996), whereas lesion 
studies suggest the left DLPFC in particular is important for letter based word fluency (Stuss 
et al., 1998). Ability to switch mental set is impaired following damage to the PFC and basal 
ganglia (Ravizza & Ciranni, 2002), and finally response inhibition performance has long been 
localised to the PFC, however of particular importance is the right inferior frontal gyrus 
(Chambers et al., 2009). The conclusions reached by Montgomery et al. (2005a) and the 
review by Murphy at al. (2009) are that ecstasy use has a stronger detrimental effect on 
updating and access, and that inhibitory control and mental set switching are unaffected by 
use. However, there are instances of ecstasy users showing no apparent deficit in function 
specific tasks that tap updating (Hanson & Luciana, 2004; Hoshi et al., 2007) and access 
(Gouzoulis-Mayfrank, 2000; Bedi & Redman, 2008) as well as instances of ecstasy-related 
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impairments in switching (von Geusau et al., 2004; Dafters 2006a) and inhibition (Yip & 
Lee, 2005). 
 Several neuroimaging studies have concluded that ecstasy related neuronal 
adaptations may occur neurophysiologically before they manifest functionally. Roberts and 
Montgomery (2015a)  suggested that ecstasy users display increased blood flow to areas of 
the PFC during a verbal fluency task, despite no differences in task performance. This 
suggests ecstasy users work harder to achieve similar performance to controls, and that 
functional differences may be apparent with increased workload. Similar conclusions have 
been drawn from EEG studies whereby ecstasy users display evidence of recruiting additional 
resources in comparison to controls, whilst showing similar performance (Burgess et al., 
2011; Roberts et al., 2013 a, b and c). Similarly, fMRI studies have shown alterations to 
neuronal activation consistent with ecstasy-related damage despite not showing any 
performance deficits (Moeller et al., 2004; Daumann et al., 2005; Jager et al., 2008; Roberts 
& Garavan, 2010). Such neuroimaging studies suggest that neurophysiological correlates of 
executive performance are present before a behavioural difference manifests itself. It remains 
plausible that many behavioural studies lack statistical power to observe subtle impairments 
over the entire spectrum of EFs. Therefore, the aim of this meta-analysis was to examine the 
evidence for overall dysfunction of executive control in ecstasy users compared to polydrug 
users, but also to examine any functional specific deficits.   
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Methods 
Eligibility criteria 
Participants 
Included studies were those assessing EF in human ecstasy/MDMA users aged 18 years+, 
who did not have a history of major psychiatric or neurological problems. Ecstasy user 
groups were eligible if they were described as current ecstasy users, control groups were 
eligible if they reported some use of drugs, but no ecstasy use – with the exception of studies 
in which the ecstasy users were recruited with the specific criteria of limited exposure to 
other drugs. In each case, participants were not intoxicated at the time of testing. The 
majority of studies included, used a minimum abstinence period of 7 days, with the exception 
of Heffernan et al., (2001), de Sola et al., (2008a) and Fagundo et al., (2010), who report a 
minimum abstinence period of 24 hours, 72 hours and 72 hours respectively. The mean age 
for ecstasy user group across studies was 23.39, with an average of 47.72% females. Mean 
lifetime dose across studies was 346.03 tablets. The mean age of the control group was 23.11, 
with an average of 54.67% females.  
Studies 
Studies comparing ecstasy users and controls in performance on behavioural tasks that are 
function-specific were eligible for inclusion. The EFs included this analysis were; updating, 
inhibitory control, switching and access. Tasks eligible for inclusion can be observed in Table 
1. There were no date limitations on publication. 
Outcome measures 
As each EF can be assessed using several tasks, there are a number of outcome measures. The 
outcome measure from each task that most clearly taps its putative EF was selected for 
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inclusion in analysis. As such each task contributes one outcome measure to the analysis 
only. Tasks included as well as the outcome measure selected can be observed in Table 1.  
Data search and extraction 
Information sources and search strategy 
The formal search strategy involved searching, 3 electronic databases during July 2015; 
PsychINFO, Scopus and Web of Science. Systematic searches used the key terms ‘Ecstasy’ 
OR ‘MDMA’ AND, ‘executive function’.  Supplementary searches were also conducted 
using the terms ‘Ecstasy’ and ‘MDMA’ combined with the name of each task in Table 1. 
Manual searches of reference sections of initially identified studies were conducted to 
supplement the formal electronic search, furthermore articles that were not identified in the 
initial searches that the authors knew to be eligible for inclusion were assessed for inclusion. 
These additional searches yielded a further 5 studies eligible for inclusion. 
<<Insert Table 1 Here>> 
Article selection and extraction of data 
Initial searches were carried out by one author (CR). However supplementary searches and 
manual searches were carried out by two authors (CR and CM). Both authors were 
responsible for the assessment of articles for inclusion, and decisions over article inclusion 
were made through discussion. One author (CR) extracted the relevant data and a second 
author (CM) cross checked this. Several studies met inclusion criteria, but did not report 
sufficient information in the manuscripts to compute the effect size, in each case data was 
requested from the corresponding author of the manuscript. Data requests were not met for 5 
articles; Semple et al., 1999; Thomasius et al., 2003; McCann et al., 2007; McCann et al., 
2008 and Fagundo et al., 2010.  
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Additional Handling of data 
Composite performance scores for letter updating, spatial updating and Random Letter 
Generation (RLG) were calculated from the available data, if the composite score itself was 
not reported in the paper. On occasions where reported values of behavioural performance 
were split by gender, a weighted mean by number in each sample was calculated. A weighted 
SD was also calculated by multiplying squared SDs by number in each group, adding these 
together, then dividing by total n. The square root of this total was then used as the SD in 
analysis. Data for the FAS task were provided by Morgan (2002), with means and SDs given 
for each letter. Therefore means for performance on each letter were added up to give a total 
score and the SDs were summed and divided by 3. 
There were a number of cases where an article had used more than one task to assess an EF 
(Fox et al., 2001; Gouzoulis-Mayfrank et al., 2003; Montgomery et al., 2005a; Wareing et al., 
2005; Lamers et al., 2006; Montgomery et al., 2007; Montgomery & Fisk, 2008; Fisk & 
Montgomery, 2009; Halpern et al., 2011). In these cases, means and SDs were entered for 
each task, however the number of participants in each group was divided by the number of 
tasks included for that function from that paper. 
In de Sola et al., (2008a and b), between group comparisons were given a year apart. For the 
meta-analysis, we used baseline measurements of lifetime drug use and task performance. In 
cases where ecstasy user groups were broken down into further subgroups e.g. ‘heavy and 
‘light’ users (as per Fisk & Montgomery, 2009), data from the heavy user group was included 
in the analysis. In Fox et al., (2001) the user groups were split into problem/non-problem 
users and low/medium/high intensity users. The group of high intensity users was included in 
the current analysis. Although the “heavy” and “high intensity” user group criteria were 
arbitrarily decided in the original papers, it seemed pertinent to include the user groups with 
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the heaviest background ecstasy use in the current analysis, as these would be the most likely 
to show ecstasy related cognitive impairment. 
Data items extracted for individual studies 
From each of the published manuscripts, the following information was extracted for each 
group: number of participants, gender split, age, estimated lifetime dose of ecstasy, time since 
last use, task used (Table 2), outcome measure (Table 1) and means and SDs for each 
outcome variable. In cases where mean ecstasy abstinence duration was not reported, the 
minimum abstinence period required for the study was recorded. If not reported in the 
manuscript, estimates of mean lifetime dose of ecstasy were calculated from the available 
data. Reported ecstasy user groups could generally be defined by two categories; current 
users and former users. There were several categories of control groups, including: cannabis 
only users, polydrug control groups (who have been recruited due to them having some 
degree of matching for other substances), non-users (this was a general catch all name given 
to controls who were ecstasy naïve but did have some other drug use) and drug naïve controls 
(no illicit substance use, but allowed for use of alcohol and nicotine). 
Statistical and subgroup analysis 
Standardised Mean Difference (SMD) and Standard Error (SE) of the SMD between 
experimental conditions were calculated for each executive task outcome separately in each 
study. SMDs were employed due to variation in outcome measures in the behavioural tasks 
included in the analysis. SMD estimates differences between 2 experimental conditions on an 
outcome variable (SMD = Mean1 – Mean2 / pooled SD). This allowed for a subgroup 
analysis to be conducted by executive function (inhibitory control, updating, access and 
switching). The meta-analysis used generic inverse variance methods to synthesise individual 
SMDs, in the software package RevMan 5.2 (The Nordic Cochrane Centre, Copenhagen). 
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The magnitude of SMDs can be interpreted thus: 0.2 = small, 0.5 =  moderate, and 0.8 = a 
large effect (Higgins & Green, 2011).  
Analytic Strategy: The meta-analysis was conducted by separating effect sizes from tasks 
employed in each study into distinct EFs. The main effect and formal sub-group analysis was 
examined, whereby each EF was considered a sub-group. 
Outcome measures of the various tasks that were included in this meta-analysis had to be 
reviewed by the authors so that the direction of differences in task performance were 
consistent for interpretation of ecstasy related impairment. For example, if ecstasy users 
produced fewer words on the verbal fluency tasks relative to controls, this would be 
indicative of ecstasy related impairment in verbal fluency and would result in a negative 
SMD in the meta-analysis. However, a greater amount of perseveration errors on the WCST 
would be indicative of impairment yet would yield a positive SMD, should ecstasy users 
produce more errors here. As such outcome measures were negatively coded where 
appropriate. 
The main analysis was conducted on the 39 studies that assessed one or more EF in a current 
ecstasy user group verses a control group that had some use of recreational drugs. Studies that 
employed a drug naïve control group and no drug user control group were not included in the 
analysis, with the exception of 3 studies (Halpern et al., 2004; Yip & Lee, 2005; Halpern et 
al., 2011). These studies were included, with a drug naïve control group, as their current 
ecstasy user groups had minimal exposure to other drugs. The remaining studies featured a 
drug using control group, as such, all between group comparisons in this meta-analysis have 
at least some degree of matching for other drug use. Random effects models were employed 
due to high heterogeneity in the data across studies. 
Results 
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Study Selection 
Initial literature searches yielded 99 papers using Web of Science, 79 using Scopus and 386 
papers from PsychINFO. After removing 76 duplicated papers, 459 articles remained. A brief 
review of the remaining articles titles and abstracts led to exclusion of 370 irrelevant articles. 
Excluded papers at this stage included; review articles (23), acute administration studies (26), 
studies that were conducted using other substances/did not involve ecstasy users (75), studies 
that were not experimental/did not include behavioural data/assess cognition (232), case 
studies (8), studies conducted in non-human samples (4), a study not written in English (1) 
and reanalyses of data (2). This left a total of 88 articles for full review. Further studies were 
excluded at this stage if they did not employ a function specific task identified in Table 1 
(35), did not employ a control group or current user group, or did not conduct between group 
analysis (10). Longitudinal studies using a within groups design and prospective studies on 
novice users were also excluded at this stage (4). Following these data exclusion procedures 
39 studies remained. A further 5 studies eligible for inclusion were identified from 
supplementary searches. Of the 44 studies that met all the inclusion criteria, data was not 
available for 5, as such the final meta-analyses were conducted on data from 39 articles. 
<<Insert Figure 1 about here>> 
Overview 
Participant characteristics 
Individual study information including sample sizes and participant characteristics are given 
in Table 2.  
<<Insert Table 2 Here>> 
Meta-analysis on executive function in ecstasy polydrug users 
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Data from 39 published studies, contributing 89 effect sizes, were included in analysis, 
including data from a total of 1221 current ecstasy users and 1242 controls. For descriptive 
information from each study see Table 2.  
Meta-analyses: 
The test for overall effects was significant (SMD = -0.18, 95% CIs [-0.26, -0.11]; Z=5.05, p < 
.001, I2 = 82%), suggesting an overall executive performance deficit in ecstasy users relative 
to controls, albeit a small effect. However there was also a significant subgroup effect (X2 = 
22.06, df = 3, p < .001, I2 = 86.4%) demonstrating differential effects across EFs. Individual 
analyses are reported below. 
Access: 
A total of 13 studies, contributing 13 effect sizes, assessed access to long term/semantic 
memory, with a total of 483 ecstasy users and 491 controls. A significant difference was 
observed between these two comparison groups (SMD = -0.33, 95% CIs [-0.46, -0.19]; Z = 
4.72, p < .001; I2 = 74%), demonstrating that ecstasy users perform poorly compared to 
controls in this EF. 
Inhibition:  
Twenty studies, contributing 20 effect sizes investigated performance difference in inhibitory 
control providing a comparison between 606 ecstasy users and 632 controls. No between 
group difference was observed in performance of this EF (SMD = 0.04, 95% CIs [-0.07, 
0.15]; Z = 0.77, p > .05). 
Switching: 
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Switching was assessed in a total of 488 ecstasy users and 459 controls, in a total of 18 
papers, contributing 23 effect sizes. There were significant between group differences in this 
function (SMD = -0.19, 95% CIs [-0.36, -0.02]; Z = 2.16, p < .05; I2 = 85%), demonstrating 
that ecstasy use leads to impairment in mental set switching. 
Updating: 
A total of 872 ecstasy users and 904 controls were compared for updating performance from 
a total of 24 articles, contributing 33 effect sizes. Again, there was a significant between 
group difference in performance of updating tasks (SMD = -0.26, 95% CIs [-0.37, -0.15]; Z = 
4.49, p < .001; I2 = 82%). This demonstrates that there is an ecstasy related impairment with 
regards to updating performance. 
<<Insert Figure 2 Here>> 
Meta-regression 
We conducted a method of moments (random-effect model) meta-regression across the 64 
comparisons included in the main meta-analysis, with the available data for estimates of 
lifetime dose of ecstasy. This was conducted to observe whether there was a relationship 
between lifetime dose of ecstasy and SMD in executive performance. The overall meta-
regression was non-significant (regression coefficient: -0.0001, 95% CIs [-0.0004, 0.0002], Z 
= -0.74, p > .05), suggesting that lifetime dose did not predict performance differences. 
Furthermore, individual meta-regressions performed separately for each specific EF were all 
non-significant (p > .05 in each case). 
 
Evidence of publication bias  
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Examination of a funnel plot revealed asymmetry, therefore an Egger’s test of publication 
bias was conducted (Egger et al., 1997) on the 89 effect sizes included in this meta-analysis. 
Egger’s test was significant (t(88)= - 1.96, p = .05), suggesting evidence of publication bias. 
However, these results should be interpreted with caution due to the  high heterogeneity 
between studies (Sterne et al., 2011).  
 
Discussion 
The results from this meta-analysis demonstrate EF deficits in current ecstasy users. 
However, the size of this overall effect was small. Subgroup analyses showed that effect sizes 
varied by the specific component of EFing. Individual analyses by function showed ecstasy 
related deficits in the EFs access, switching and updating, though there was no inhibition 
performance deficit.  
 Meta-regression using estimated lifetime dose of ecstasy to predict effect size of 
between group differences was non-significant. This suggests that lifetime dose is not the 
greatest predictor in magnitude of EF deficit. However there were 9 studies (providing 25 
comparisons) that did not give lifetime estimates of use and so were not included in the 
analysis, which may have potentially given a different outcome. Nevertheless, there was high 
variability in effects and although estimates of lifetime use were not possible for all studies, 
there were 64 comparisons from 30 studies which did include estimated lifetime dose, which 
is far greater than the minimum of 10 required for adequate power in a meta-regression 
(Borenstein et al., 2009). Despite adequate power to detect an effect, it could be that the 
analysis is conceptually flawed, given that it is conducted on SMDs in performance between 
ecstasy users and controls rather than estimated lifetime dose and task performance (Murphy 
et al., 2012). Alternatively, it could be that there are other ecstasy using behaviours that have 
a stronger impact on behavioural measures, for example recency of use, frequency of use and 
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higher nightly doses. Recency of use has been identified as a predictor of haemodynamic 
response to a cognitive task in ecstasy users (Roberts & Montgomery, 2015b). Furthermore, 
higher nightly doses may impact cognition more than cumulative intake, indeed a single high 
dose of MDMA is enough to cause neurotoxicity in lab animals (Molliver et al., 1990). 
Unfortunately there is substantial variance in the reporting of drug use histories in the 
literature, limiting interpretation. Perhaps some unity on background drug use reporting 
would vastly improve research and our understanding of harmful behaviours. We propose a 
unified reporting criterion should be applied to future research. There are also a number of 
variables that may contribute to the impact of cumulative dose (Murphy et al., 2012)  
including earlier onset of use, use of other drugs, and increased bioenergetic stress (Parrott, 
2009). 
 Neuronal regions implicated in working memory and EF include the DLPFC and the 
hippocampus (depending on the nature of the task). These structures have dense innervation 
of 5-HT neurons (Pazos et al., 1987; Curtis & D’Esposito, 2003). Therefore ecstasy related 
degradation to the serotonin system, through neurotoxicity or down-regulation following 
chronic recent use, is understood to be a potential cause of cognitive impairment in the 
functions supported by these areas. If ecstasy is a serotonin-specific neurotoxin in humans as 
it is in animals (Green et al., 2003), one would expect functional alterations following 
repeated use. Several molecular imaging studies in human ecstasy users suggest a reduction 
in pre-synaptic SERT availability in areas including the frontal cortex (McCann et al., 1998; 
Kish et al., 2010) and the DLPFC (McCann et al., 2005). Increases in post-synaptic 5-HT2A 
receptors have also been observed in ecstasy users relative to controls in the DLPFC (Urban 
et al., 2012). Decreased pre-synaptic SERT and increased post-synaptic 5-HT2A receptor 
availability are consistent with serotonin axon damage. Moreover functional neuroimaging 
studies have observed ecstasy related adjustments to cerebral blood flow in frontal areas, with 
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fNIRS (Roberts & Montgomery, 2015a) and fMRI (Moeller et al., 2004; Jager et al., 2008; 
Roberts & Garavan, 2010). It is noteworthy that all of the functional imaging studies 
mentioned observe increased neuronal activity to achieve similar behavioural performance to 
controls. This suggests that molecular and functional neuroimaging detect changes in 
serotonin signalling which cause future deficits in EF. The current results support this by 
demonstrating behavioural correlates for the supposed neuronal degradation. 
 Ecstasy-related impairments in switching were unexpected, given that previous 
reviews in this area have concluded that this function is relatively stable (Murphy et al., 
2009). However, some studies have observed significant switching differences between 
ecstasy users and controls (Halpern et al., 2004; Dafters, 2006a) and neuroimaging studies 
have suggested atypical processing during switching (Roberts, 2013c). This highlights the 
necessity for larger samples to elucidate this performance deficit.  However, this difference 
was the weakest of the 3 significant differences and had a small effect size; thus it should be 
treated with caution. The reduced performance in updating and access in ecstasy users 
relative to controls is more consistent with previous reports (Montgomery et al., 2005a; 
Murphy et al., 2009). Nevertheless there have been previous reports of null findings in these 
functions. The ability to update ones memory is reflective of the concept of working memory 
as a whole, and Miyake and co-workers (Friedman et al., 2006; Miyake & Friedman, 2012) 
maintain that updating is the key over-arching EF which is important for daily function.  
 Although, not unexpected, it is interesting to consider why there were no apparent 
group differences in inhibitory control. One explanation could be that ecstasy users are high 
functioning impulsives and this increased impulsivity serves to mask performance deficits on 
the tasks employed here (Fritsche et al., 2011). Alternatively, perhaps inhibitory control 
impairment is associated with other psychostimulants that are primarily dopaminergic in 
nature, e.g. cocaine (Fillmore & & Rush, 2002) and methamphetamine (Monterosso et al., 
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2005). Interestingly, in recent models of the unity and diversity of EFs, Miyake & Freidman 
(2012) confer that inhibitory control is not necessarily a unique EF. Instead, inhibitory 
control is subsumed by common EF ability. With this in mind, it could be suggested that 
ecstasy users, are therefore impaired at each level of EF. 
 There are a number of limitations of the current analysis. Concomitant use of other 
drugs is often posited to contribute to the cognitive deficits displayed by ecstasy users. To try 
and incorporate this in to the meta-analysis, comparisons were made between ecstasy users 
and controls that have at least some experience with drugs other than ecstasy. Nevertheless, it 
should be noted that in many of the studies in the analysis, the use of drugs other than ecstasy 
was, in fact, higher in the ecstasy user groups than the polydrug control groups (in terms of 
total lifetime dose, frequency of use and variety of drugs used). As such, we cannot rule out 
the possibility that alcohol and other drugs may also contribute to deficits in executive 
functioning. However despite the increased polydrug use among ecstasy user groups, there 
are several instances of drug use indices predicting unique variance in executive  functions in 
regression analyses (for example Schilt et al., 2008), this suggests that various chronic drug 
effects do show independence from one another. Increased cohesion in reporting of drug use 
variables would help to remove some of this uncertainty in future. Similarly, it cannot be 
ruled out that the direction of causality is interpreted incorrectly. It could be that, individuals 
with EF deficits are more likely to have a stronger propensity for ecstasy use, though the 
authors think that this is unlikely. Future  research should concentrate on longitudinal studies 
to obviate confusion over direction of causality. Furthermore, as the current analysis is 
conducted on current users and therefore cannot make any predictions about function 
recovery following abstention, longitudinal studies may also help to determine whether 
recovery is possible. The current results suggest that ecstasy users may struggle with higher 
level executive functioning, and it has been suggested that such impairments would lead to 
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difficulty in performing the majority of occupational tasks (Parrott, 2013). Montgomery et al. 
(2010) observed ecstasy users to be impaired at a virtual reality office work task, with the 
suggestion that office work, as well as those occupations requiring greater executive 
resources will be adversely affected by ecstasy use. Taken together, these findings suggest 
that prolonged ecstasy use can lead to everyday functioning problems; therefore an 
understanding of the processes underpinning such impairments may prove valuable to 
clinicians 
 To conclude, the current meta-analysis demonstrated that EF performance in ecstasy 
users is significantly reduced overall compared to controls. The three functions that show 
significant impairment are updating, switching and access, whilst inhibitory control is 
unaffected by ecstasy use. This is the most comprehensive analysis of EF in ecstasy users to 
date and provides a behavioural correlate of potential serotonergic neurotoxicity. 
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 Table 1: Tasks included for assessment of each executive function.  
Executive Function Task Outcome measure 
   
Inhibitory control Stroop Stroop interference RT 
 RLG Composite task score (reverse scored) 
 Go NoGo NoGo errors 
  Or NoGo correct responses (reverse 
scored) 
 Eriksen Flankers task Interference cost 
 Stop signal Stop signal reaction time 
   
Switching Stroop switch Switch RT 
 ToL Total movements / solution time / 
proportion of perfect solutions 
  Or solution time 
 3D ID-ED Simple reversal (switch cost) 
 WCST Perseverative errors 
 Trail Making Test B Time  
 Stockings of Cambridge  
 Number-Letter Task Switch cost 
 Plus-Minus Task Switch cost 
 Dots-Triangles Task Switch cost 
 Local-Global Task Switch cost 
 Rule Shift Cards Test Task score 
   
Updating Keep Track Words 
 Computation Span Task Score 
 Consonant/letter Updating Composite score 
 Spatial Updating Composite score 
 Digit Span Backwards Task Score 
 2-Back Letters Correct responses 
 2-Back Figures Correct responses 
 Spatial Span Backwards Task score 
 Subtracting Serial Sevens errors 
 Mental Counters Correct responses 
   
Access COWA/FAS/Word fluency Total words 
 CWFT – C letter words  Total words 
 CWFT – standardised score Composite score 
 Semantic Retrieval Task Low association errors 
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Table 2: Summary of studies included in meta-analysis on executive function in current ecstasy users and drug using controls 
Authors and Study Participants and Design Task(s) used Result 
Bedi & Redman (2008) 
 
45 ecstasy polydrug users (47% F, mean age: 22.8±3.0, 
MLD = 170.6±362.8, MTSLU = 79.2±108.5 days). 
48 Cannabis polydrug users (46% F, mean age = 
21.7±3.5) 
COWA FAS  No between group differences in 
original analysis 
Croft et al. (2001) 
 
11 MDMA and cannabis users (55% F, mean age: 
27.5±4.7, MLD = 41.9 (49.3), no ecstasy abstinence data 
given). 
18 cannabis users (22% F, mean age: 26.6±8.1) 
COWA FAS  
Stroop  
Digit span backwards 
No differences in performance 
between MDMA users and cannabis 
users 
Dafters (2006a) 
 
33 ecstasy and cannabis users (36% F, mean age: 
23.09±2.34, MLD = 499.1±671.56, min abstinence = 5 
days). 
18 non-users (44% F, mean age: 22.67) 
Stroop  
Stroop switch) 
Keep track  
Ecstasy users, significantly impaired 
on task-switching Stroop, but not in 
Stroop interference or Keep Track 
Task.  
Dafters (2006b) 18 ecstasy and cannabis users (33% F, mean age: 
23.24±2.33, MLD = 522.33±936.71, min abstinence = 5 
days). 
18 non-users (44% F, mean age: 22.67±2.56) 
Stroop  No significant between group 
differences 
de Sola et al. (2008a) 
 
37 ecstasy polydrug users (49% F, mean age: 23.6±3.5, 
MLD = 206±228.3, min abstinence = 72h). 
23 cannabis users (65% F, mean age: 22.0±1.9) 
ToL  No significant between group 
differences at baseline 
de Sola et al. (2008b) 
 
14 ecstasy polydrug users (57% F, mean age = 
25.2±3.3, MLD = 207.4±151.0, no abstinence data 
given). 
13 cannabis users (61% F, mean age: 25.1±2.9) 
ToL No significant between group 
differences at baseline 
Fisk & Montgomery (2009) 
 
14 heavy ecstasy users (36% F, mean age: 22.86, MLD 
= 1000.21±786.41, MTSLU = 22 weeks). 
28 non-users (75% F, mean age: 20.71) 
RLG  
Computation span  
Consonant updating  
Spatial updating  
Heavy user not impaired at RLG . All 
updating measures show ecstasy 
related deficits, and these were 
significant in 2 out of 3 measures. 
Fisk et al. (2004) 
 
44 ecstasy users (mean age: 21.52±1.66, MLD = 
343.38±376.94, MTSLU = 10.90±27.86 weeks). 
59 non-users (mean age: 21.37±1.84) 
RLG 
Computation span  
 
 
No group differences on RLG 
performance. Ecstasy users 
significantly impaired on computation 
span 
Fox et al. (2001) 
 
11 high intensity ecstasy users (45% F, mean age: 
28.0±5.3, MTSLU = 2.8±5.9 months). 
20 polydrug controls (70% F, mean age: 23.3±6.5) 
WCST  
 
ToL  
No between group differences in 
WCST perseverative errors or ToL 
solution time 
Fox et al. (2002) 
 
20 ecstasy polydrug users (50% F, mean age: 27.3±6.7, 
MLD = 172.0±227.36, MTSLU =  51.9±25.9 months). 
20 polydrug controls (60% F, mean age: 27.5±7.6) 
3D IDED  No between group differences 
Gouzoulis-Mayfrank et al. 
(2000) 
 
28 ecstasy users (43% F, mean age: 23.25, MDL = 
93.4±119.9, MTSLU = 41±71.1 days). 
28 polydrug controls (46% F, mean age: 22.9) 
 
Stroop  
Digit span backwards  
Phonological word 
fluency  
 
Ecstasy users performed worse than 
non-users in digit span backwards. 
No performance differences 
observed in Stroop interference or 
word fluency 
29 
 
Gouzoulis-Mayfrank et al. 
(2003) 
 
30 heavy ecstasy users (30% F, mean age: 25.1±4.65, 
MDL = 503.2±555.5, MTSLU = 194.8±351.8 days). 
30 non-users (30% F, mean age: 25.37±2.72) 
 
Go NoGo  
 
Digit span backwards  
2back letters  
2back figures  
No differences between ecstasy 
users and controls in central 
executive function. 
 
 
Halpern et al. (2004) 
 
23 ecstasy users with minimal exposure to other drugs 
(65% F, mean age: 20, MDL = 60 episodes). 
16 controls equally involved in rave culture (44% F, 
mean age: 22) 
COWA FAS  
Stroop  
WCST 
Digit span backwards  
 
No between group differences in 
FAS, WCST, Stroop or digit span 
backwards. However ecstasy related 
impairment on digit span backwards 
when adjusted for age and sex 
Halpern et al. (2011) 
 
52 ecstasy users (46% F, mean age: 22, MDL = 43.5 
episodes, MTSLU = 121 days). 
59 non-users (36% F, mean age: 24) 
Spatial span backwards  
Digit span backwards  
Stroop  
WCST 
TMT-B  
No significant between group 
differences on any of the executive 
measures. 
Hanson & Luciana (2004) 
 
26 ecstasy users (46% F, mean age: 21.3±3.6, MLD = 
123.31, MTSLU = 10.9±10.5 weeks). 
26 non-users (46% F, mean age: 20.7±3.4) 
COWA FAS  
Digit span backwards  
No between group differences in 
COWA total words, or digit span 
backwards performance 
Heffernan et al. (2001) 
 
30 regular ecstasy users (43% F, mean age: 23.9±4.47, 
min TSLU = 24h). 
37 ecstasy free controls (73% F, mean age: 25.5±8.76) 
Word fluency, C letter 
words  
Ecstasy users performed significantly 
worse than controls in verbal fluency 
measure. 
Hoshi et al. (2007) 
 
25 ecstasy users (mean age: 28.64±4.59, MLD = 
1111.68, MTSLU = 14.2 days). 
29 polydrug users (mean age: 31.93±8.41) 
 
Subtracting serial 
sevens  
Verbal fluency  
TMT-B  
Go Nogo  
No significant group differences were 
found in Serial Sevens, verbal 
fluency, the TMT. 
 
Lamers et al. (2006) 
 
11 MDMA/THC users (mean age: 22.9±2.4, MTSLU = 
228.1±140.3 days) 
15 cannabis users (mean age: 24.3±5.3) 
TMT-B  
 
WCST  
No between group effects on TMT-B 
or WCST 
McCardle et al. (2004) 
 
17 ecstasy users (24% F, mean age: 21.06±1.56), 
MTSLU = 130 days). 
15 controls (13% F, mean age: 21.91±1.62) 
Digit span backwards  
TMT-B  
 
No between group effects observed 
in digit span backwards or TMT-B 
Montgomery & Fisk (2008) 
 
73 ecstasy polydrug (47% F, mean age: 21.77±2.11, 
MLD = 309.86±486.25, MTSLU = 32.15±62.82 weeks). 
73 non-ecstasy users (73% F, mean age: 20.73±1.73) 
Letter updating  
Spatial updating 
Ecstasy users impaired in four out of 
six sub-sample analyses.  
Montgomery et al. (2005a) 
 
Study 1: 27 ecstasy users (48% F, mean age: 
21.70±1.66, MLD = 345.96±365.76, MTSLU = 4.97±7.27 
weeks). 
34 non-users (71% F, mean age: 21.59±1.88) 
 
Study 2: 51 ecstasy users (47% F, mean age: 
21.96±2.11, MLD = 373.87±542.91, MTSLU = 22.15 
weeks). 
42 non-users (79% F, mean age: 20.83±1.45) 
CWFT C letter words  
Computation span) 
Letter updating  
Number-letter task 
Plus-minus task  
RLG  
 
Ecstasy users performed worse on 
both  updating tasks and access to 
long-term memory tasks. 
 
Ecstasy users performed significantly 
better on the inhibition task. No group 
differences were observed in 
switching. 
Montgomery et al. (2005b) 
 
22 MDMA users (50% F, mean age: 21.36±1.67, MLD = 
303.3±374.04, MTSLU = 4.61±6.82 weeks). 
26 non-MDMA users (62% F, mean age: 21.31±1.69) 
RLG – task score 
(inhibition) 
Computation span – 
task score (updating) 
Ecstasy users performed significantly 
worse than non-users in the 
computation span task. There were 
30 
 
 no group differences in RLG 
performance 
Montgomery et al. (2007) 
 
104 ecstasy users (mean age: 21.68±1.96, MLD = 
349.97±464.41, MTSLU = 19.35±43.46 weeks). 
103 non-users (mean age: 21.11±1.66) 
CWFT  
Computation span  
Letter updating  
Ecstasy users performed worse than 
controls on all measures 
Morgan (1998) 
 
Study 1: 16 ecstasy users (50% F, mean age: 
20.94±1.88, MLD = 35.5±17.5, MTSLU = 20.4±33.6 
days). 
12 polydrug controls (mean age: 20.25±1.48). 
 
Study 2: 25 ecstasy users (52% F, mean age: 
22.28±2.48, MLD = 49.6±33.2, MTSLU = 65.1±85.7). 
20 polydrug controls (mean age: 23±4.71) 
ToL No between group differences of ToL 
performance in either study 
Morgan et al. (2002) 
 
18 ecstasy users (50% F, mean age: 23.4±3.2, MLD = 
303±267.5, MTSLU = 4.05±3.2 weeks). 
16 polydrug users (50% F, mean age: 22.1±3.3) 
 
TMT-B  
COWA FAS  
Stroop  
Subtracting serial 
sevens  
Ecstasy users worse on SSS than all 
groups. However, no between group 
differences observed in verbal 
fluency, Stroop interference RT, or 
TMT-B completion time. 
Murphy et al. (2011) 
 
15 ecstasy and cannabis users (73% F, mean age: 
24.5±3.4, MLD = 364.8±665.1, MTSLU = 365 days). 
13 cannabis users (54% F, mean age: 21.9±4.6) 
RLG  
 
Ecstasy users had significantly 
higher redundancy on RLG than drug 
naïve controls but not cannabis 
controls 
Nulsen et al. (2011) 
 
11 ecstasy users (64% F, mean age: 22.9±2.6, MLD = 
32.5±27.2). 
13 polydrug controls (70% F, mean age: 23.2±3.3) 
Digit span backwards  
 
No significant between group 
differences in digit span backwards 
performance 
Reay et al. (2006) 
 
15 ecstasy polydrug users (40% F, mean age: 25±5.8, 
MLD = 593.4). 
15 polydrug controls (53% F, mean age = 21.3±538) 
Digit span backwards  
Brixton spatial 
anticipation task  
Inhibition of return 
 
Ecstasy users performed significantly 
worse on digit span backwards and 
the Brixton spatial anticipation task. 
No between group differences 
observed in inhibition of return 
Reneman et al. (2006) 
 
23 heavy ecstasy (48% F, mean age: 26.05±5.05, MLD = 
516.35±452.1, MTSLU = 2.29±2.39 months). 
15 polydrug controls (53% F, mean age: 26.3±4.1) 
 
COWA FAS  
Stroop  
WCST  
TMT-B  
No between group differences overall 
on executive functioning 
Roberts et al. (2013a) 
 
20 ecstasy polydrug users (50% F, mean age: 
23.95±2.50, MLD = 177.65±301.73, min abstinence = 7 
days). 
20 polydrug controls  (55% F, mean age = 22.58±3.45) 
Go NoGo  No between group differences in 
NoGo errors 
Roberts et al. (2013b) 
 
20 ecstasy polydrug users (50% F, mean age: 
23.95±2.50, MLD = 177.65±301.73, min abstinence = 7 
days). 
20 polydrug controls  (55% F, mean age = 22.58±3.45) 
Semantic retrieval task  No behavioural between group 
differences 
Roberts et al. (2013c) 
 
20 ecstasy polydrug users (50% F, mean age: 
23.95±2.50, MLD = 177.65±301.73, min abstinence = 7 
days). 
20 polydrug controls  (55% F, mean age = 22.58±3.45) 
Number-letter task  No behavioural between group 
differences 
Rodgers (2000) 
 
15 ecstasy users (53% F, mean age: 31 years 5 months, 
MLD = 20 occasions, min abstinence = 2 months). 
Digit span  
 
No performance difference in digit 
span 
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15 cannabis users (53% F, mean age = 30 years 3 
months) 
von Geusau et al. (2004) 
 
26 ecstasy users (35% F, mean age: 21.55±1.3, min 
abstinenece = 2 weeks). 
33 non-users (64% F, mean age: 21.7±2.1) 
WCST  
ToL  
Stop signal task  
Mental counters  
 
Male MDMA users performed worse 
on tasks that tap cognitive flexibility. 
No differences were observed on 
other cognitive tasks. Female users 
showed no impairments 
Wareing et al. (2004) 
 
42 ecstasy users (48% F, mean age: 21.69±2.57, MLD = 
552.99±681.41, MTSLU = 3±3.66 weeks). 
31 non-users (61% F, mean age: 23.39±6.47) 
Computation span  
 
MDMA users performed significantly 
worse than controls on computation 
span task 
Wareing et al. (2005) 
 
36 ecstasy users (mean age: 21.81, MLD = 
591.33±718.44, MTSLU = 3.30±3.87). 
31 non-users (mean age: 23.39±6.47) 
Spatial working memory 
span 
Computation span 
Ecstasy users (users and former 
users) show impaired spatial working 
memory compared to controls. 
Wareing et al. (2007) 
 
29 ecstasy users (mean age: 21.72±2.00, MLD = 
536±515.73, MTSLU = 1.86±1.50 weeks). 
46 non-users (mean age: 22.85±5.50) 
Computation span  
 
Both ecstasy user groups performed 
significantly worse than non-users on 
the computation span measure 
Yip & Lee (2005) 
 
100 ecstasy users (mean age: 28.48±5.71, MLD = 
35.81±13.21, MTSLU = 2.23±0.51 months). 
100 non-users (mean age: 28.82±5.78) 
 
Stroop  
Digit span backwards 
 
 
No between group differences on 
backwards digit span. However 
ecstasy users performed significantly 
worse at the Stroop task 
Zakzanis & Young (2001) 
 
30 ecstasy users (67% F, mean age: 22.96, MLD = 
37.76, MTSLU = 19.96 weeks). 
24 non-users (67% F, mean age: 19.54) 
Rule shift cards test  No significant difference between 
groups in rule shift cards test 
performance 
MLD = Mean lifetime dose, MTSLU = Mean time since last use. Information on previous exposure to other drugs and other groups not included in the meta-analysis can be viewed online ( supplementary material) 
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Figure 1: Meta-analysis search results and flow chart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
564 articles identified from initial database 
searches 
76 removed due to duplication 
459 titles and abstracts screened 
370 articles removed due to not being relevant to the current 
analysis. 
Reviews, acute administration, other substances/did not involve 
ecstasy users, were not experimental/did not include 
behavioural data/assess cognition, case studies,  non-human 
samples and reanalyses of data 88 articles eligible for full text review. 
 
A further 49 articles removed after full text review 
Reasons for exclusion: No function specific task, no control group 
or current user group. Longitudinal studies using a within groups 
design and prospective studies on novice users 
39 articles Identified for inclusion from 
electronic searches. 
5 additional articles identified for inclusion 
from additional searches 
5 articles excluded due to unobtainable data 
39 articles identified for meta-analysis 
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